dm+d
73572009
Articles
Morphine products: information for supporting intrathecal risk assessment
11 August 2022Morphine sulfate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Using opioids for pain relief during pregnancy
10 August 2022Opioid analgesics may be used at any stage of pregnancy at the lowest effective dose for the short-term relief of pain when other analgesics are not effective
Example medicines to prescribe by brand name in primary care
27 March 2022Prescribe certain medicines by brand to ensure supply of the same product. Examples are grouped by therapeutic area. The list of products is not exhaustive.
Supply and/or administration of Controlled Drugs under a Patient Group Direction
16 November 2021This article summarises the legal position on the supply and/or administration of controlled drugs under PGDs.
An example oral opioid switch from morphine to oxycodone
14 September 2021An example worked scenario to support you when switching or advising on switching between morphine and other oral opioids in cancer and palliative care
Medicine Compliance Aid Stability
ZomorphEthypharm UK
Ethypharm UK
Zomorph
Capsules m/r - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light. Airtight container. Protect from heat.
22 November 2022
SevredolNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
Sevredol
Tablets f/c - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light.
17 November 2022
Morphgesic SRAdvanz Pharma
Advanz Pharma
Morphgesic SR
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light.
22 November 2022
MST ContinusNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MST Continus
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light
17 November 2022
MXLNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MXL
Capsules m/r - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light. Airtight container.
22 November 2022
Lactation Safety Information
Except for low dose, immediate release oral formulations
Except for low dose, immediate release oral formulations
Other appropriate analgesic
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Used in full-term neonates from birth
Infant monitoring advised, especially in young infants (see summary)
23 September 2020
Low dose, immediate release oral formulations
Low dose, immediate release oral formulations
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Applies to short term, low dose (up to 10mg 4-hourly) oral solutions (e.g. Oramorph) and tablets
Although adverse effects in infant are not likely infant monitoring advised in young infants (see summary)
23 September 2020
New Medicines
ActimorphSevere pain which can only be managed with opioids, in adults and children aged 6 months and older - orodispersible formulation
Information
Actimorph
New formulation
Ethypharm
Not Known
Development and Regulatory status
Launched
None
None
April 2022
Apr 22Actimorph available in the UK. Price for a pack of 56: 1mg=£2.00; 2.5mg=£2.50; 5mg=£3.50; 10mg=£4.75; 20mg=£9.50; 30mg=£13.00.[4]
Mar 22Actimorph will be available in the UK from 1 May 2022 [3].
Jul 21MHRA approves Actimorph orodispersible tablets for severe pain which can be adequately managed only with opioids. Licensed for use in adults and children aged 6 months and older. An immediate-release formulation available in 1mg, 2.5mg, 5mg, 10mg, 20mg and 30mg strengths [2].
Category
An agonist at opiate receptors in the CNS particularly mu and to a lesser extent, kappa receptors. Mu receptors are thought to mediate supraspinal analgesia, respiratory depression and euphoria and kappa receptors, spinal analgesia, miosis and sedation. Formulated as an immediate-release orodispersible tablets and available in the following strengths: 1mg, 2.5mg, 5mg, 10mg, 20mg and 30mg.
Strong opioids such as morphine are useful for moderate-to-severe pain, particularly of visceral origin. Long-term prescribing is most common for palliative care in malignant disease but also may be appropriate for chronic non-malignant conditions, in conjunction with specialist advice. Long-term opioids have proved disappointing in the management of chronic non-cancer pain [1].
Severe pain which can only be managed with opioids, in adults and children aged 6 months and older - orodispersible formulation
Oral